Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical …
G Agiostratidou, H Anhalt, D Ball, L Blonde… - Diabetes …, 2017 - Am Diabetes Assoc
OBJECTIVE To identify and define clinically meaningful type 1 diabetes outcomes beyond
hemoglobin A1c (HbA1c) based upon a review of the evidence, consensus from clinical …
hemoglobin A1c (HbA1c) based upon a review of the evidence, consensus from clinical …
Dapagliflozin: a review of its use in patients with type 2 diabetes
GL Plosker - Drugs, 2014 - Springer
Abstract Dapagliflozin (Forxiga®, Farxiga®) is an orally administered sodium-glucose co-
transporter-2 (SGLT2) inhibitor used in the management of patients with type 2 diabetes …
transporter-2 (SGLT2) inhibitor used in the management of patients with type 2 diabetes …
Dapagliflozin in patients with type 2 diabetes mellitus
TD Filippatos, EN Liberopoulos… - … in endocrinology and …, 2015 - journals.sagepub.com
Dapagliflozin is a selective and reversible inhibitor of sodium–glucose linked transporter
type 2 (SGLT2), which mediates approximately 90% of active renal glucose reabsorption in …
type 2 (SGLT2), which mediates approximately 90% of active renal glucose reabsorption in …
Person‐reported outcomes in diabetes care: What are they and why are they so important?
N Hermanns, B Kulzer… - Diabetes, Obesity and …, 2024 - Wiley Online Library
In this review, we aim to show how person‐reported outcomes (PROs) and person‐reported
experiences (PREs) can significantly contribute to the way diabetes care is delivered, the …
experiences (PREs) can significantly contribute to the way diabetes care is delivered, the …
Cost effectiveness of dapagliflozin added to standard of care for the management of diabetic nephropathy in the USA
Background Angiotensin-converting enzyme inhibitors have been used as the standard of
care for the treatment of diabetic nephropathy. Recently, dapagliflozin has been shown to …
care for the treatment of diabetic nephropathy. Recently, dapagliflozin has been shown to …
[HTML][HTML] Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)
H Nakajima, S Okada, T Mohri, E Kanda… - Diabetology & metabolic …, 2018 - Springer
Background The benefits of sodium glucose cotransporters 2 (SGLT2) inhibitors in patients
with type 2 diabetes mellitus include plasma glucose control, reduction in body weight and …
with type 2 diabetes mellitus include plasma glucose control, reduction in body weight and …
Effects of Sodium‐Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic …
K Yabiku, K Nakamoto… - Journal of Diabetes …, 2020 - Wiley Online Library
Many blood glucose‐lowering drugs cannot be used once patients with type 2 diabetes
(T2D) and nonalcoholic fatty liver disease develop nonalcoholic steatohepatitis (NASH) …
(T2D) and nonalcoholic fatty liver disease develop nonalcoholic steatohepatitis (NASH) …
Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleepquality, quality of life, and anxiety levels in people with type 2 diabetes mellitus …
S Şahin, Ö Haliloğlu, ÖP Korkmaz… - Turkish Journal of …, 2021 - journals.tubitak.gov.tr
Background/aim: To evaluate the impact of treatment with sodium-glucose co-transporter-2
(SGLT2) Inhibitors on quality of life (QoL), sleep quality (SQ), and anxiety levels in patients …
(SGLT2) Inhibitors on quality of life (QoL), sleep quality (SQ), and anxiety levels in patients …
[HTML][HTML] Quality-of-life comparison of dapagliflozin versus dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes mellitus: A randomized controlled trial (J …
H Ishii, H Nakajima, N Kamei, T Niiya, T Hiyoshi… - Diabetes Therapy, 2020 - Springer
Introduction No study has compared the effects of sodium–glucose cotransporter 2 inhibitors
(SGLT2is) and dipeptidyl peptidase 4 inhibitors (DPP4is) on patients' quality-of-life (QOL) …
(SGLT2is) and dipeptidyl peptidase 4 inhibitors (DPP4is) on patients' quality-of-life (QOL) …
Association of SGLT‐2 Inhibitors With Treatment Satisfaction and Diabetes‐Specific and General Health Status in Adults With Cardiovascular Disease and Type 2 …
Q Ding, ES Spatz, JF Bena, SL Morrison… - Journal of the …, 2023 - Am Heart Assoc
Background It is unknown if initiation of a sodium‐glucose cotransporter‐2 inhibitor (SGLT‐
2i) is associated with changes in patient‐reported health status outside of clinical trials …
2i) is associated with changes in patient‐reported health status outside of clinical trials …